The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population
Abstract
The metabolic syndrome and alcohol risk use are both associated with a high prevalence of hepatic steatosis, but only a minority develop liver failure or liver cancer. Few general population studies have analyzed metabolic predictors of such severe liver complications. We studied which metabolic factors best predict severe liver complications, stratified by alcohol consumption, in 6732 individuals without baseline liver disease who participated in the Finnish population-based Health 2000 Study (2000-2001), a nationally representative cohort. Follow-up data from national registers until 2013 were analyzed for liver-related admissions, mortality, and liver cancer. Baseline alcohol use and metabolic factors were analyzed by backward stepwise Cox regression analysis. Eighty-four subjects experienced a severe liver event during follow-up. In the final multivariate model, factors predictive of liver events were age (hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.004-1.04), sex (women: HR, 0.55; 95% CI, 0.34-0.91), alcohol use (HR, 1.002; 95% CI, 1.001-1.002), diabetes (HR, 2.73; 95% CI, 1.55-4.81), low-density lipoprotein (LDL) cholesterol (HR, 0.74; 95% CI, 0.58-0.93), and homeostasis model assessment of insulin resistance (HOMA-IR) (HR, 1.01; 95% CI, 1.004-1.02). Among alcohol risk users (≥210 g/week for men, ≥ 140 g/week for women), diabetes (HR, 6.79; 95% CI, 3.18-14.5) was the only significant predictor. Among nonrisk drinkers, age, alcohol use, smoking, waist circumference, low LDL cholesterol and HOMA-IR were significant independent predictors. The total-to-LDL cholesterol ratio and waist circumference-to-body mass index ratio emerged as additional independent predictors. CONCLUSION: Multiple components of the metabolic syndrome independently affected the risk for severe liver disease. Alcohol was significant even when average alcohol consumption was within the limits currently defining nonalcoholic fatty liver disease. (Hepatology 2018;67:2141-2149).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Equally important may be the possible synergy between alcohol consumption and the presence of metabolic risk factors for liver disease progression, 75,83 with the strongest effect for central obesity.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [84]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“assessment of insulin resistance (HOMA-IR) served as an estimate of insulin resistance and was calculated using the following equation as described previously (those on insulin treatment were excluded)((23)): fasting insulin (lU/mL)3 fasting glucose (mmol/L)/22.”
MethodCancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60121-5 · Cited by 1,892
The burden of liver disease in Europe: A review of available epidemiological data
Blachier, M., Leleu, H., Peck‐Radosavljevic, M., Valla, D. C., & Roudot‐Thoraval, F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.005 · Cited by 1,340
Body Mass Index, Waist Circumference, and Health Risk
Janssen, I., Katzmarzyk, P. T., & Ross, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2074 · Cited by 969
Alcohol as a risk factor for liver cirrhosis: A systematic review and meta‐analysis
REHM, J., TAYLOR, B., MOHAPATRA, S., IRVING, H., BALIUNAS, D., PATRA, J., & ROERECKE, M. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00153.x · Cited by 668
Excess weight risk factor for alcoholic liver disease
Naveau, S., Giraud, V., Borotto, E., Aubert, A., Capron, F., & Chaput, J. (1997) · Hepatology · doi:10.1002/hep.510250120 · Cited by 666 · cited 3×
“ALD and NAFLD are currently distinguished from each other by an arbitrary threshold of average alcohol Abbreviations: ALD, alcoholic liver disease; BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; HR, hazard ratio; LDL, low-densi…”
BackgroundHart, C. L., Morrison, D. S., Batty, G. D., Mitchell, R. J., & Davey Smith, G. (2010) · BMJ · doi:10.1136/bmj.c1240 · Cited by 422
Risk factors of fibrosis in alcohol-induced liver disease
Raynard, B., Balian, A., Fallik, D., Capron, F., Bédossa, P., Chaput, J., & Naveau, S. (2002) · Hepatology · doi:10.1053/jhep.2002.31782 · Cited by 387
Cited by
Sorted by citations
Items 201–267 of 267
Epidemiology of Chronic Liver Diseases
Engel, B., & Manns, M. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-82930-8_1 · Cited by 3
Zhang, N., Li, J., Xie, X., Hu, Y., Chen, H., Zhang, Y., Liu, Y., Zhu, X., Xu, H., Wang, Z., et al. (2025) · BMC Public Health · doi:10.1186/s12889-025-21752-1 · Cited by 3
Fan, H. X., Zhang, P., Liu, Z., Zhao, R., Suo, C., Chen, X., & Zhang, T. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00214 · Cited by 3
Effects of low ethanol consumption on nonalcoholic steatohepatitis in mice
Takahashi, Y., Watabe, S., Togashi-Kumagai, A., Watanabe, M., Dungubat, E., Kusano, H., Kobayashi, Y., Harada, N., Yamaji, R., Sugimoto, K., et al. (2020) · Alcohol · doi:10.1016/j.alcohol.2020.04.004 · Cited by 3
Attribution of diabetes to the development of severe liver disease in the general population
Vuorinen, M., Männistö, V., Salomaa, V. V., Britton, A. R., Jula, A., Männistö, S., Lundqvist, A., Perola, M., & Åberg, F. O. (2022) · Liver International · doi:10.1111/liv.15296 · Cited by 3
Targher, G. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.59 · Cited by 3
Alcohol and Metabolic Syndrome Interaction
Hashida, R., Golabi, P., Ong, J. P., Kawaguchi, T., & Younossi, Z. M. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.06.002 · Cited by 2
Diabetes mellitus in alcohol-associated liver disease: Prevalence and outcomes
Ward, B., Theodoreson, M. D., Aithal, G. P., Allison, M., Brahmania, M., Forrest, E. H., Hagström, H., Masson, S., McCune, A., Naik, K., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000734 · Cited by 2
“Patients with DM had a lower serum bilirubin concentration (13 mmol/L [9 – 32] vs. 25 [12 – 95], p 0.001) and lower MELD at baseline (8 [6 – 12] vs. 11 [7 – 18], p 0.001).”
InfluentialPustjens, J., van Kleef, L. A., Younossi, Z. M., Moreno, C., Janssen, H. L. A., Thiele, M. S., & Brouwer, W. P. (2025) · Hepatology Research · doi:10.1111/hepr.70067 · Cited by 2
Treatment approaches for alcohol use disorder with metabolic dysfunction
Wagner, A. C., Jung, J., Pacher, P., & Lohoff, F. W. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108957 · Cited by 4
Mihaila, D. F., Domnariu, H. P., Moga, D. F. C., & Domnariu, C. D. (2026) · Metabolites · doi:10.3390/metabo16040224 · Cited by 2
“Several studies evaluated the combined effects of metabolic dysfunction and alcohol consumption on liver outcomes, consistently demonstrating synergistic interactions [6–11 , 39– 41 ].”
InfluentialPekarska, K., Rowe, I. A. C., & Parker, R. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10033-5 · Cited by 2
“Prior studies have similarly shown that MASLD patients with light to moderate alcohol intake remain at risk of fibrosis progression and clinical liver disease [45].”
Esmailzadeh, A., Norouzkhani, N., Dokhtfaroughi, S. S., Rasoulian, A., & Habibi, M. R. M. (2026) · Health Science Reports · doi:10.1002/hsr2.72636 · Cited by 2
Jarvis, H., Brennan, P., Casanovas, T., Casler, K., Desai, M., Evans, P. H., Dillon, J. F., Grattagliano, I., Hallsworth, K., Hebditch, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00015-4 · Cited by 3
Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment
Qadri, S. U. (2026) · Diabetologia · doi:10.1007/s00125-026-06816-0 · Cited by 2
“MetALD is an overlap syndrome in which abdominal obesity and excessive alcohol use act as synergistic drivers of disease severity, and it may carry a worse prognosis than MASLD alone [3, 17–20].”
Díaz, L. A., Pose, E., Israelsen, M. E., & Loomba, R. S. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01240-6 · Cited by 3
Okyere, J., Salu, S., Ayebeng, C., & Dickson, K. S. (2024) · Discover Public Health · doi:10.1186/s12982-024-00129-6 · Cited by 2
“Undoubtedly, alcohol consumption (particularly heavy drinking) is a high risk factor for many adverse health outcomes including obesity [26], cardiovascular diseases [27], cancer [28], and liver diseases [29].”
Feng, X., Xuan, R., Dong, Y., Wu, X., Cheng, Y., Yuan, Z., Dong, H., Han, J., Zhong, F., Zhao, J., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13030488 · Cited by 2
“In the presence of metabolic risk factors, moderate alcohol consumption appears to be significantly more damaging to the liver [18,19].”
BackgroundConsenso Mexicano de hepatitis alcohólica
Velasco, J. A. V.-R., la Tijera, F. H., Castro‐Narro, G., Zamarripa-Dorsey, F., Abdo-Francis, J. M., Haddad, I. A., Ledesma, J. M. A., Bielsa-Fernández, M. V., Reyes, E. C., Cisneros-Garza, L. E., et al. (2020) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2020.04.002 · Cited by 2
Liver fibrosis scores in the general population: Better risk indices are needed!
Åberg, F. O. (2017) · Hepatology · doi:10.1002/hep.29710 · Cited by 2
Mallet, M., & Saliba, F. (2019) · Liver International · doi:10.1111/liv.14169 · Cited by 2
A research study on the utility of GGT level and AST/ALT ratio in alcoholic liver diseases
Sivasubramaniam, R. (2024) · International Journal of Clinical Biochemistry and Research · doi:10.18231/j.ijcbr.2024.015 · Cited by 1
Lazo, M., Li, J., Hirsch, J. A., Moore, K., Auchincloss, A. H., Tabb, L. P., Barrientos‐Gutiérrez, T., Clark, J. M., Solga, S. F., Budoff, M. J., et al. (2024) · Health & Place · doi:10.1016/j.healthplace.2024.103392 · Cited by 1
Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
Özercan, M., Tawheed, A., & El‐Kassas, M. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001273 · Cited by 1
Huang, J., Zou, W., Lv, Z., Han, H., Huang, J., & Su, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-97429-x · Cited by 1
Schult, A., Mehlig, K., Svärdsudd, K., Wallerstedt, S., Björkelund, C., Hansson, P., Zetterberg, H., & Kaczynski, J. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i6.107160 · Cited by 1
Yeo, Y. H., Rui, F., Zhu, Y., Xu, X., Ma, X., Ni, W., Sun, Y., Hu, X., Wu, C., Shi, J., et al. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70015 · Cited by 1
Premkumar, M. H., Sandhu, A., Sharma, P., Nain, J., Bhujade, H., Gupta, P. C., De, A., Verma, N., Duseja, A. K., Surender, et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001822 · Cited by 1
Alcohol-related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study
Szabó, G., Kamath, P. S., Shah, V. H., Thursz, M. R., & Mathurin, P. (2018) · Hepatology · doi:10.1002/hep.30473 · Cited by 1
Possibilities of a new assessment scale for prediction of chronic liver disease “CLivD”
Lazebnik, L. B., & Туркина, С. В. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-219-11-62-66 · Cited by 1
Hsu, M.-F., Koike, S., Chen, C.-S., Najjar, S. M., Meng, T., & Haj, F. G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116590 · Cited by 1
Latest Insights in Alcohol-Related Liver Disease and Alcoholic Hepatitis
Enciu, V.-T., Ologeanu, P. M., Constantinescu, A., & Fierbinteanu-Braticevici, C. G. (2025) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2025-0007 · Cited by 1
The importance of preventing alcohol-related liver disease in the USA
Shield, K. D., & Rehm, J. T. (2020) · The Lancet Public Health · doi:10.1016/s2468-2667(20)30118-3 · Cited by 1
Bernardo, S., Crespo, R. R., Saraiva, S. L., Barata, R., Gonçalves, S., Nogueira, P., Cortez‐Pinto, H., & Machado, M. V. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252218 · Cited by 1
Chen, M.-S., Wang, H., Guo, H., Zhang, Y., & Chen, L. (2021) · Cancers · doi:10.3390/cancers14010085 · Cited by 2
Marcellin, F., Costa, M., Wittkop, L., Protopopescu, C., Esterle, L., Salmon, D., Sogni, P., & Carrieri, P. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0270-x · Cited by 1
Neuropsychiatry: Emotional Factors in Disease.
ALLEN, C. L. (1928) · PubMed
Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap
Reddy, S. S. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00542-w
Diagnostic Considerations in Metabolic Disease Associated with Obstructive Sleep Apnea
Bourey, R. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-54146-0_5
Effects of Ethanol Feeding in Early-Stage NAFLD Mice Induced by Western Diet
Brol, M. J., Georgiou, S., Rasmussen, D. N., Ortiz, C., Klein, S., Schierwagen, R., Uschner, F. E., Eberle, L., Detlefsen, S., Pantazopoulou, V. I., et al. (2021) · Livers · doi:10.3390/livers1010003
“Large cohort analyses revealed that alcohol consumption, even within the acceptable limit for the diagnosis of NAFLD, negatively affects the severity of chronic liver disease in patients with metabolic syndrome [19].”
BackgroundWang, L., Xu, Y. S., & Bi, Y. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.02.006
Skin metabolic syndrome and phytonutrients
Sureda, A., & Tejada, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824356-5.00001-1
Alcohol-related liver diseases
Wang, H. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2022-1202
Modulation of Alcohol-Related Liver Disease by Obesity and Diabetes
Hegmar, H., & Hagström, H. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_51
Zhang, P., Yang, S., Yu, P., Zeng, Y., Ye, C., Wang, P., Wang, M., Li, L., & Dong, X. (2024) · Research Square · doi:10.21203/rs.3.rs-4081675/v1
STUDI LITERATUR SISTEMATIS TENTANG PENGARUH KONSUMSI ALKOHOL TERHADAP PENYAKIT LIVER KRONIK
Hernando, W. I., & Hernanda, P. Y. (2024) · Calvaria Medical Journal. · doi:10.30742/cmj.v2i1.40
Jiang, H., Zhou, J., Cai, X., Hu, B., Wang, H., Fu, C., Xu, N., Gong, Y., Tong, Y., Yin, J., et al. (2024) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trae052
Solís‐Muñoz, P. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09076-x
“Studies suggest that MASLD patients who drink less than 20 g/day(women) or 30 g/day(men) still face increased risk of fibrosis and hepatocellular carcinoma compared with those that are abstinent [2, 4].”
A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD
Razzak, I. A., Razzak, I. A., Noureddin, M., & Trivedi, H. D. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002210 · Cited by 1
Grip, E. T., Shang, Y., Skröder, H., Modica, A., Ström, O., Ntanios, F. Y., Guðbjörnsdóttir, S., & Hagström, H. (2025) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2025.100276
DeVore, Z., McNamara, P., Belkin, D., Ganjoo, N., & Devuni, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-823524-9.00004-6
Nanomaterials in Targeted Drug Delivery for Metabolic Syndrome
Sen, G., Patel, P. K., Malang, S. D., Kathait, P., Ankur, Yadav, N. K., Otimenyin, S. O., & Sahu, A. N. (2025) · Springer eBooks · doi:10.1007/978-981-95-3746-4_5
Additional file 1 of Response to semaglutide of non-drinker subjects with type 2 diabetes
Petralli, G., Raggi, F., Zoppo, A. D., Rovera, C., Salvati, A., Brunetto, M. R., & Solini, A. (2024) · Figshare · doi:10.6084/m9.figshare.25853087
Tu, L., Hu, H., Zhou, X., Zhang, H., Liu, X., Yang, D., & He, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25271827
Abassa, K.-K., Yu, H., Tan, S., Li, M., Zhong, Z., Zhou, H., & Guo, Y. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113027
Dunn, W., Krag, A. A., Kamath, P. S., & Singal, A. K. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.007
Yu, L.-Y., & Zhang, X. (2026) · World Journal of Hepatology · doi:10.4254/wjh.117543
Steatotic liver disease subtypes and risk of hospitalization for sepsis: a nationwide cohort study
Seong, H., Kim, S. Y., Lee, E. H., Kim, D., Han, K., & Han, S. H. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2704290
“MetALD represents a clinically important overlap state in which metabolic dysfunction and increased alcohol intake coexist [32].”
Coronel-Castillo, C. E., Parraga, X., Sierra, L., Arrese, M. A., Arab, J. P., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.78
Feng, J., Yuan, F., Xu, R.-B., Ma, X.-P., Gasparetto, R., Mueller, E. G., Kim, S., He, L.-Q., Warner, D. R., McClain, C. J., et al. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00916
Zheng, J., Song, Y., 徐, 浩., Feng, B., & 谢艳迪 (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1861502
Niriella, M. A., Karunanayake, R. C., Wickramasuriya, H. P., & Silva, A. P. D. (2026) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2026.100718
Rønn, J. H., Jepsen, P., Mellinger, J. L., Innes, H. A., Eliasen, M., Christensen, A. I., Madsen, L. G., & Askgaard, G. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.017
Molecular Pathogenesis and Risk Factors Underlying ALD
Seth, D., & Murali, T. (2026) · Springer eBooks · doi:10.1007/978-3-031-35658-2_194-1
Metadata
- Authors
- Åberg, F., Helenius‐Hietala, J., Puukka, P., Färkkilä, M., & Jula, A.
- Affiliations
- University of Helsinki (FI)
- Department of Health,National Institute for Health and Welfare,Turku,Finland
- Corresponding author
- Åberg, Fredrik
- Venue
- Hepatology
- Published
- 2018-04-16
- Volume
- 67
- Issue
- 6
- Pages
- 2141-2149
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2770566262
- Cited by
- 267
- References
- 32
- Citations by year
- 2026: 20 · 2025: 32 · 2024: 46 · 2023: 28 · 2022: 30 · 2021: 31 · 2020: 34 · 2019: 26 · 2018: 16
- FWCI
- 16.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Finska Läkaresällskapet
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- alcohol consumption, metabolic syndrome, severe liver disease, liver failure, liver cancer, non-alcoholic fatty liver disease, diabetes mellitus, insulin resistance, HOMA-IR, LDL cholesterol, waist circumference, smoking, risk factors, liver-related mortality, general population, Finland, sex differences
- MeSH terms
- Alcohol Drinking, Female, Humans, Liver Diseases, Male, Middle Aged, Prognosis, Prospective Studies, Risk Factors, Severity of Illness Index, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
